- Generic name
- Rabeprazole Sodium
- Strength
- 20 mg
- Dosage form
- Tablet
- Manufactured by
- United Chemicals & Pharmaceuticals Ltd.
Stogut 20 Tablet
About Stogut 20 Tablet
Stogut 20 is a 20 mg tablet containing rabeprazole sodium, used for stomach ulcers and acid reflux disease. It lowers stomach acid and helps relieve related symptoms.
There are 48 brands of Rabeprazole Sodium listed in Bangladesh. The lowest listed price is Acifix 10 mg Sprinkle Capsule at ৳ 3.50 per unit.
What is Stogut 20 Tablet?
Stogut 20 is a tablet made by United Chemicals & Pharmaceuticals Ltd. that contains rabeprazole sodium 20 mg. It belongs to a group of medicines called proton pump inhibitors. It works by reducing the amount of acid produced in the stomach. Doctors prescribe it for active duodenal ulcer, active benign gastric ulcer, and symptoms of erosive or ulcerative gastro-esophageal reflux disease (GERD). It is also used for long-term management of GERD and for moderate to very severe GERD symptoms. The dose and length of treatment are decided by your doctor.
Uses of Stogut 20
Stogut 20 is used to treat active duodenal ulcer and active benign gastric ulcer. It is also used for symptomatic erosive or ulcerative gastro-esophageal reflux disease (GERD) and for long-term management of GERD. Additionally, it helps with symptoms of moderate to very severe gastro-esophageal reflux disease. Your doctor will confirm whether this medicine is suitable for your condition.
How to use Stogut 20
Take Stogut 20 exactly as your doctor tells you. The tablet is usually taken by mouth, but the doctor will decide the dose and how long you need to take it. Do not change the dose or stop early without asking your doctor. Swallow the tablet whole with water, unless your doctor or pharmacist gives different instructions. If you forget a dose, ask your doctor or pharmacist what to do.
Side effects of Stogut 20
Like all medicines, Stogut 20 can cause side effects, though not everyone gets them. Reported side effects include headache, diarrhoea, abdominal pain, vomiting, constipation, dry mouth, increased or decreased appetite, muscle pain, drowsiness and dizziness. If you notice any side effect or it becomes troublesome, tell your doctor or pharmacist. Do not stop or change the medicine on your own.
Safety and precautions
Do not take Stogut 20 if you are allergic to rabeprazole or any ingredient of the tablet. It is not recommended during pregnancy or breastfeeding. Tell your doctor if you are pregnant, planning pregnancy or breastfeeding. Before starting treatment, your doctor should rule out stomach or oesophageal cancer, because symptoms can improve even when a serious condition is present. If you take long-term treatment, especially for more than a year, you should be checked regularly. Ask your doctor first if you have any other health problems or take other medicines.
Frequently asked questions
How should I store Stogut 20?
Keep the tablets below 30°C, away from light and moisture. Store them out of the reach of children. Do not use after the expiry date printed on the pack. If you are unsure about storage, ask your pharmacist.
What is Stogut 20 used for and what kind of medicine is it?
Stogut 20 is a proton pump inhibitor. It is used for active duodenal ulcer, active benign gastric ulcer, and symptoms of erosive or ulcerative GERD, as well as long-term GERD management. It works by reducing stomach acid. Your doctor will decide if it is right for you.
Who should avoid Stogut 20 or ask the doctor first?
Do not take it if you are allergic to rabeprazole or any ingredient. It is not recommended in pregnancy or breastfeeding. Tell your doctor if you are pregnant, breastfeeding, or have other health conditions. Your doctor should rule out stomach or oesophageal cancer before you start.
Can I stop taking Stogut 20 when I feel better?
Do not stop taking Stogut 20 without talking to your doctor. Your doctor will decide how long you need to take it. Stopping early may affect your treatment. Always follow your doctor's advice about the course of treatment.
Indications
- Active duodenal ulcer
- Active benign gastric ulcer
- Symptomatic erosive or ulcerative gastro-esophageal reflux disease (GERD).
- Gastro-esophageal Reflux Disease Long-term Management (GERD Maintenance) ... Read more
- Active duodenal ulcer
- Active benign gastric ulcer
- Symptomatic erosive or ulcerative gastro-esophageal reflux disease (GERD).
- Gastro-esophageal Reflux Disease Long-term Management (GERD Maintenance)
- Symptomatic treatment of moderate to very severe gastro-esophageal reflux disease (symptomatic GERD)
- Zollinger-Ellison Syndrome
- In combination with appropriate antibacterial therapeutic regimens for the eradication of Helicobacter pylori in patients with peptic ulcer disease.
Pharmacology
Dosage & Administration
Erosive or Ulcerative Gastro-Esophageal Reflux Disease (GERD): The recommended oral dose for this condition is 20 mg to be taken once daily for four to eight weeks.
Gastro-Esophageal Reflux Disease Long-term Management (GERD Maintenance): For long-term management, a maintenance dose of rabeprazole sodium 20 mg or 10 mg once daily can be used depending upon patient response.
Symptomatic treatment of moderate to very severe Gastro-Esophageal Reflux Disease (symptomatic GERD): 10 mg once daily in patients without oesophagitis. If symptom control has not been achieved during four weeks, the patient should be further investigated. Once symptoms have resolved, subsequent symptom control can be achieved using an on-demand regimen taking 10 mg once daily when needed.
Treatment of GERD in pediatric patients 1 to 11 years of age (Less than 15 kg): 5 mg once daily for 12 weeks with the option to increase to 10 mg if inadequate response.
Treatment of GERD in pediatric patients 1 to 11 years of age (15 kg or more): 10 mg once daily for 12 weeks.
Zollinger-Ellison Syndrome: The recommended adult starting dose is 60 mg once a day. The dose may be titrated upwards to 120 mg/day based on individual patient needs. Single daily doses up to 100 mg/day may be given. 120 mg dose may require divided doses, 60 mg twice daily. Treatment should continue for as long as clinically indicated.
Eradication of H. pylori: Patients with H. pylori infection should be treated with eradication therapy. The following combination given for 7 days is recommended. Rabeprazole sodium 20 mg twice daily, clarithromycin 500 mg twice daily and amoxicillin 1g twice daily.
Interaction
Contraindications
Side Effects
Pregnancy & Lactation
Precautions & Warnings
- Symptomatic response to therapy with Rabeprazole does not preclude the presence of gastric or oesophageal malignancy, therefore the possibility of malignancy should be excluded prior to commencing treatment with Rabeprazole 20 mg Gastro-resistant Tablets.
- Patients on long-term treatment (particularly those treated for more than a year) should be kept under regular surveillance.
- Proton pump inhibitors, especially if used in high doses and over long durations (>1 year), may modestly increase the risk of hip, wrist and spine fracture, predominantly in the elderly or in presence of other recognised risk factors. Observational studies suggest that proton pump inhibitors may increase the overall risk of fracture by 10–40%. Some of this increase may be due to other risk factors. Patients at risk of osteoporosis should receive care and they should have an adequate intake of vitamin D and calcium.
- A risk of cross-hypersensitivity reactions with other proton pump inhibitor or substituted benzimidazoles cannot be excluded.
- Patients should be cautioned that Rabeprazole gastro-resistant tablets should not be chewed or crushed, but should be swallowed whole.
- There have been post marketing reports of blood dyscrasias (thrombocytopenia and neutropenia). In the majority of cases where an alternative aetiology cannot be identified, the events were uncomplicated and resolved on discontinuation of rabeprazole.
- Hepatic enzyme abnormalities have been seen in clinical trials and have also been reported since market authorisation. In the majority of cases where an alternative aetiology cannot be identified, the events were uncomplicated and resolved on discontinuation of rabeprazole.
- No evidence of significant drug related safety problems was seen in a study of patients with mild to moderate hepatic impairment versus normal age and sex matched controls. However because there are no clinical data on the use of rabeprazole in the treatment of patients with severe hepatic dysfunction the prescriber is advised to exercise caution when treatment with Rabeprazole 20mg Gastro-resistant. Tablets is first initiated in such patients.
- Co-administration of atazanavir with Rabeprazole is not recommended.
- Treatment with proton pump inhibitors, including rabeprazole, may possibly increase the risk of gastrointestinal infections such as Salmonella, Campylobacter and Clostridium difficile.
Influence on vitamin B12 absorption: Rabeprazole sodium, as all acid-blocking medicines, may reduce the absorption of vitamin B12 (cyanocobalamin) due to hypo- or a- chlorhydria. This should be considered in patients with reduced body stores or risk factors for reduced vitamin B12 absorption on long-term therapy or if respective clinical symptoms are observed.
Subacute cutaneous lupus erythematosus (SCLE): Proton pump inhibitors are associated with very infrequent cases of SCLE. If lesions occur, especially in sun-exposed areas of the skin, and if accompanied by arthralgia, the patient should seek medical help promptly and the health care professional should consider stopping Rabeprazole. SCLE after previous treatment with a proton pump inhibitor may increase the risk of SCLE with other proton pump inhibitors.
Interference with laboratory tests: Increased Chromogranin A (CgA) level may interfere with investigations for neuroendocrine tumours. To avoid this interference, Rabeprazole 20mg Gastro-resistant Tablets treatment should be stopped for at least 5 days before CgA measurements. If CgA and gastrin levels have not returned to reference range after initial measurement, measurements should be repeated 14 days after cessation of proton pump inhibitor treatment.
Overdose Effects
Storage Conditions
Alternative brands of Rabeprazole Sodium
Other brands with the same generic name, cheapest first.
Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.